RSV Found in Aerosol Particles Surrounding Infants With RSV

Share this content:
RSV Found in Aerosol Particles Surrounding Infants With RSV
RSV Found in Aerosol Particles Surrounding Infants With RSV

FRIDAY, Aug. 12, 2016 (HealthDay News) -- Infants with respiratory syncytial virus (RSV)-positive bronchiolitis produce large numbers of aerosol particles containing RSV that remain infectious for a significant length of time, according to a study published in the Aug. 1 issue of the American Journal of Respiratory and Critical Care Medicine.

Hemant Kulkarni, from the University of Leicester in the United Kingdom, and colleagues used viable impactor sampling to measure the amount of RSV contained in aerosolized particles produced by infants with bronchiolitis due to RSV. They determined the ability of RSV contained in these particles to infect healthy and chronic obstructive pulmonary disease (COPD) human ciliated respiratory epithelium.

The researchers found that infants with RSV-positive bronchiolitis nursed in a ward setting or ventilated in intensive care produced large numbers of RSV-containing aerosol particles. These particles remained infectious and were able to infect both healthy and COPD human ciliated epithelium. Particles with aerodynamic diameters of less than 5 µm had a significant amount of RSV.

"Many of the aerosolized particles that contained RSV in the air surrounding infants with bronchiolitis were sufficiently small to remain airborne for a significant length of time and small enough to be inhaled and deposited throughout the respiratory tract," the authors write. "It is likely that this leads to spread of infection to others, with dissemination of infection throughout the respiratory tract."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »